<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555163</url>
  </required_header>
  <id_info>
    <org_study_id>MD.15.165.</org_study_id>
    <nct_id>NCT02555163</nct_id>
  </id_info>
  <brief_title>Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT)</brief_title>
  <acronym>HoLERBT</acronym>
  <official_title>Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor (HoLERBT) Versus Conventional Transurethral Resection Of Bladder Tumors (cTURBT): A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial aiming to assess Holmium Laser En Bloc Resection Of Bladder Tumor&#xD;
      (HoLERBT) in comparison with Conventional Transurethral Resection Of Bladder Tumors (cTURBT)&#xD;
      in tumor histopathological staging quality, detrusor muscle sampling in biopsy, completeness&#xD;
      of tumor resection and peri procedure complication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urothelial carcinoma of the bladder is the 2nd most common urological malignancy and it makes&#xD;
      a growing healthcare problem worldwide.&#xD;
&#xD;
      The vast majority of newly diagnosed are non-muscle bladder cancers (NMIBC) which represents&#xD;
      about 75% and can be treated with transurethral resection of bladder tumors (TURBT) so,&#xD;
      correct initial staging is critical. The quality of TURBT strongly determines patient&#xD;
      prognosis and overall treatment.&#xD;
&#xD;
      Conventional transurethral resection of bladder tumors (cTURBT) causes fragmentation,&#xD;
      artifacts, thermal damages and tangential sections that might hamper histopathological&#xD;
      evaluation.&#xD;
&#xD;
      The expert meeting at Davos of the European Association of Urology (EAU) section of&#xD;
      Uro-Technology (ESUT) and the section of Uro-Oncology (ESOU) identified en bloc resections of&#xD;
      bladder tumors (ERBT) using various energy sources or modified resection loops as a promising&#xD;
      technique.&#xD;
&#xD;
      Laser therapy for the treatment of non muscle invasive bladder tumor (NMIBC) was first&#xD;
      reported in the 1970s. Neodymium:YAG lasers were mainly used for tissue vaporization.&#xD;
      Afterward, the introductions of en bloc resection methods have laser treatments for bladder&#xD;
      cancer regains its popularity. The most commonly used are holmium (Ho:YAG) and thulium&#xD;
      (Tm:YAG).&#xD;
&#xD;
      EBRBT overall complication rate of 0.7%, of which all complications had not been&#xD;
      life-threatening. Compared conventional TURBT to HoLERBT, a significant reduction of&#xD;
      obturator nerve reflex, related bladder perforations, peri- or postoperative bleeding was&#xD;
      rare, reduction in bladder irrigation time in comparison with conventional TURB. Better&#xD;
      histopathological results were with laser en bloc resection of bladder cancer by lowering of&#xD;
      thermal damage The study will be conducted in a single tertiary centre at Urology and&#xD;
      Nephrology Center in Mansoura, Egypt.&#xD;
&#xD;
      Eligible patient presented with papillary bladder tumor will be asked to participate in this&#xD;
      study and will be provided with an informed consent form in line with Good Clinical Practise&#xD;
      and the Declaration of Helsinki.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>residual disease at re-staging transurethral bladder biopsy</measure>
    <time_frame>4 weeks after primary procedure</time_frame>
    <description>Rebiopsy of the tumor base for detection of any residual disease at re staging TUR 4 weeks after primary procedure. Number of patients with residual disease at restaginf TUR will be counted in each arm and compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>periprocedure complications</measure>
    <time_frame>2 days</time_frame>
    <description>Modified Clavien scale will be used for reporting and comparison of periprocedure complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients surviving for one year without tumor recurrence will be counted and compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>HoLERBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cTURBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Transurethral Resection Of Bladder Tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HoLERBT</intervention_name>
    <description>Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer</description>
    <arm_group_label>HoLERBT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cTURBT</intervention_name>
    <description>using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces</description>
    <arm_group_label>cTURBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed at the out-patient cystoscopy with papillary bladder tumour will be&#xD;
             legible for inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor criteria&#xD;
&#xD;
               -  Non papillary gross features of the tumor&#xD;
&#xD;
               -  Anteriorly located tumor&#xD;
&#xD;
          -  Patients criteria&#xD;
&#xD;
          -  Poor performance status&#xD;
&#xD;
          -  History of BCG sepsis&#xD;
&#xD;
          -  History of bladder irradiation&#xD;
&#xD;
          -  Contracted bladder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Elshal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura urology and nephrology center, Mansoura University, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology and Nprhology Center</name>
      <address>
        <city>Mansoura</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed Elshal</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>bladder cancer, laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

